New Study Validates Hi-C Sequencing for Comprehensive Lymphoma Insights
Why are traditional methods for detecting rearrangements in lymphoid cancers falling short, and how can advanced sequencing technologies bridge this gap? Arima Genomics, a leader in leveraging whole-genome sequence and structure information, has announced the publication of a groundbreaking study from collaborators at the University of Michigan and New York University (NYU). The research, published in the scientific journal Cell Genomics, highlights the superior capabilities of Arima’s Aventa™ Lymphoma test in identifying clinically relevant rearrangements from routine FFPE specimens. This advancement addresses the limitations of conventional methods and provides deeper insights for more precise cancer therapy selection.
The study, which applied FFPE-compatible Hi-C sequencing to 44 archival FFPE biopsies across multiple lymphoid malignancies, demonstrated high concordance with standard techniques while uncovering additional clinically relevant findings. “This study from our collaborators at the University of Michigan and NYU provides further evidence of how the whole-genome approach enabled by Hi-C sequencing addresses the limitations of conventional methods for the detection of rearrangements that drive classification and care decisions in lymphoid cancers,” said Anthony Schmitt, PhD, Senior Vice President of Science at Arima Genomics. These findings underscore the growing body of evidence supporting Aventa Lymphoma and its ability to deliver clinically relevant rearrangement insights from standard FFPE specimens.
Key Insights at a Glance
- High Concordance: The study showed high agreement with standard techniques.
- Additional Findings: Clinically relevant rearrangements not detected by routine methods were identified.
- Whole-Genome View: A single assay provides a comprehensive view of rearrangements.
- Clinical Relevance: Insights help refine patient risk profiles and guide therapy selection.
Why Traditional Methods Fall Short in Lymphoid Cancer Diagnostics
Traditional methods like fluorescence in situ hybridization (FISH) typically assess the rearrangement status of only one gene per test, limiting their scope and clinical utility. This narrow focus can miss unexpected or uncommon rearrangements that are crucial for accurate diagnosis and treatment. The limitations of these methods can lead to incomplete or inaccurate patient profiles, potentially affecting treatment outcomes. As the incidence of lymphoid cancers continues to rise, the need for more comprehensive diagnostic tools becomes increasingly urgent.
The Regulatory Clock Is Already Running for Lymphoid Cancer Diagnostics
Just as a marathon runner must pace themselves to finish strong, Arima Genomics is positioning itself to lead the race in advanced cancer diagnostics. By offering a whole-genome view of rearrangements, the Aventa Lymphoma test not only addresses current diagnostic challenges but also sets a new standard for future research and clinical practice. The regulatory landscape is evolving, and companies that can provide more comprehensive and accurate insights will be better positioned to meet the growing demands of the healthcare industry.
Arima Genomics Redefines Lymphoid Cancer Diagnostics with Aventa Lymphoma
Arima Genomics is redefining cancer diagnostics with its Aventa Lymphoma test, the first whole-genome, NGS-based clinical test for gene fusion and rearrangement detection in B- and T-cell lymphomas. Leveraging Arima’s proprietary Hi-C sequencing technology, Aventa Lymphoma reports on 417 genes, providing the insights clinicians need to deliver precise diagnoses, classify subtypes, refine patient risk profiles, and guide therapy selection. This comprehensive approach ensures that even limited sample input can yield actionable insights, making it a valuable tool for oncologists and researchers alike.
Future Outlook
The publication of this study marks a significant milestone in the validation of Hi-C sequencing for lymphoid cancer diagnostics. As the technology continues to evolve, it is likely to play an increasingly important role in the standardization of cancer care. The next steps for Arima Genomics include expanding the application of Aventa Lymphoma to a broader range of cancers and further refining the technology to enhance its clinical utility. The company’s commitment to advancing cancer diagnostics is evident in its ongoing research and development efforts.
Conclusion
The advancements in whole-genome sequencing technologies, as demonstrated by Arima Genomics, are reshaping the landscape of lymphoid cancer diagnostics. For oncologists and researchers, this means more precise and comprehensive insights that can improve patient outcomes. How is your practice preparing to integrate these advanced diagnostic tools? Join the conversation in the comments below.
About Aventa Lymphoma
Aventa Lymphoma is the first whole-genome, NGS-based clinical test for gene fusion and rearrangement detection in B- and T-cell lymphomas. Leveraging Arima’s proprietary Hi-C sequencing technology and reporting on 417 genes, it provides the insights clinicians need to provide precise diagnoses, classify subtypes, refine patient risk profiles, and guide therapy selection even from limited sample input.
About Arima Genomics
Arima Genomics is redefining cancer diagnostics using whole-genome sequence and structure information. Arima’s assays enable a new era of comprehensive, clinically actionable therapy selection insights. The company serves oncologists through its CLIA-certified Aventa clinical testing laboratory in Orlando, Florida, and supports discovery-stage researchers worldwide with advanced kits and informatics.
Source link: https://www.businesswire.com/
